Cargando…

Cilostazol induced migraine does not respond to sumatriptan in a double blind trial

BACKGROUND: Cilostazol is an inhibitor of phosphodiesterase 3 and thus causes accumulation of cAMP. It induces migraine-like attacks in migraine patients. Whether the cilostazol model responds to sumatriptan in migraine patients and therefore is valid for testing of future anti-migraine medications...

Descripción completa

Detalles Bibliográficos
Autores principales:	Falkenberg, Katrine, Dunga, Bára Óladóttir á, Guo, Song, Ashina, Messoud, Olesen, Jes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796931/ https://www.ncbi.nlm.nih.gov/pubmed/29396788 http://dx.doi.org/10.1186/s10194-018-0841-7

Ejemplares similares

Pre-treatment with sumatriptan for cilostazol induced headache in healthy volunteers
por: Falkenberg, Katrine, et al.
Publicado: (2018)

Effect of CGRP and sumatriptan on the BOLD response in visual cortex
por: Asghar, Mohammad S., et al.
Publicado: (2012)

EHMTI-0033. The phosphodiesterase 3 inhibitor cilostazol induces migraine-like attacks via cAMP increase
por: Song, G, et al.
Publicado: (2014)

Histamine and migraine revisited: mechanisms and possible drug targets
por: Worm, Jacob, et al.
Publicado: (2019)

Sumatriptan does not change calcitonin gene-related peptide in the cephalic and extracephalic circulation in healthy volunteers
por: Hansen, Jakob Møller, et al.
Publicado: (2009)

PACAP signaling is not involved in GTN- and levcromakalim-induced hypersensitivity in mouse models of migraine
por: Guo, Song, et al.
Publicado: (2022)

Correction: PACAP signaling is not involved in GTN- and levcromakalim-induced hypersensitivity in mouse models of migraine
por: Guo, Song, et al.
Publicado: (2023)

Pharmacokinetics of sumatriptan in non-respondent and in adverse drug reaction reporting migraine patients
por: Sternieri, E., et al.
Publicado: (2005)

Investigation of sumatriptan and ketorolac trometamol in the human experimental model of headache
por: Ghanizada, Hashmat, et al.
Publicado: (2020)

Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine
por: Cady, Roger K., et al.
Publicado: (2017)

CGRP in migraine
por: Tfelt-Hansen, Peer, et al.
Publicado: (2009)

The K(ATP) channel in migraine pathophysiology: a novel therapeutic target for migraine
por: Al-Karagholi, Mohammad Al-Mahdi, et al.
Publicado: (2017)

Therapeutic novelties in migraine: new drugs, new hope?
por: Do, Thien Phu, et al.
Publicado: (2019)

Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
por: Ashina, Messoud, et al.
Publicado: (2020)

The effect of sumatriptan on cephalic arteries - 3T MR-angiography study in healthy volunteers
por: Amin, FM, et al.
Publicado: (2013)

Efficacy of Sumatriptan/Placebo versus Sumatriptan/Propofol Combination in Acute Migraine; a Randomized Clinical Trial
por: Farahmand Rad, Reza, et al.
Publicado: (2022)

Correction to: Therapeutic novelties in migraine: new drugs, new hope?
por: Do, Thien Phu, et al.
Publicado: (2019)

Comparison between Intravenous Sodium Valproate and Subcutaneous Sumatriptan for Treatment of Acute Migraine Attacks; Double-Blind Randomized Clinical Trial
por: Rahimdel, Abolghasem, et al.
Publicado: (2014)

Targeting enkephalins and pituitary adenylate cyclase-activating polypeptide (PACAP) in migraine
por: Ashina, Messoud
Publicado: (2022)

The changing faces of migraine
por: Martelletti, Paolo, et al.
Publicado: (2019)

Subcutaneous delivery of sumatriptan in the treatment of migraine and primary headache
por: Moore, Johanna C, et al.
Publicado: (2012)

Influence of sumatriptan on the autonomic system during migraine attacks
por: Dalla Volta, G., et al.
Publicado: (2006)

Harnessing Intranasal Delivery Systems of Sumatriptan for the Treatment of Migraine
por: Assadpour, Sara, et al.
Publicado: (2022)

Provoked versus spontaneous migraine attacks: pathophysiological similarities and differences
por: Ashina, Håkan, et al.
Publicado: (2022)

Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs)
por: Martelletti, Paolo, et al.
Publicado: (2019)

Comparison of tolerability and efficacy of a combination of paracetamol + caffeine and sumatriptan in the treatment of migraine attack: a randomized, double-blind, double-dummy, cross-over study
por: Pini, Luigi Alberto, et al.
Publicado: (2012)

The Use of Neuroimaging for Predicting Sumatriptan Treatment Response in Patients With Migraine
por: Wu, Jr-Wei, et al.
Publicado: (2022)

Treatment with sumatriptan 50 mg in the mild phase of migraine attacks in patients with infrequent attacks: a randomised, double-blind, placebo-controlled study
por: Tfelt-Hansen, P., et al.
Publicado: (2006)

Sumatriptan 6 mg subcutaneous as an effective migraine treatment in patients with cutaneous allodynia who historically fail to respond to oral triptans
por: Diamond, S., et al.
Publicado: (2007)

Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study
por: Landy, Stephen, et al.
Publicado: (2018)

The pharmacological effect of BGC20-1531, a novel prostanoid EP(4) receptor antagonist, in the Prostaglandin E(2) human model of headache
por: Antonova, Maria, et al.
Publicado: (2011)

Cutaneous nociception and neurogenic inflammation evoked by PACAP38 and VIP
por: Schytz, Henrik Winther, et al.
Publicado: (2010)

Pharmacokinetics study of chitosan-coated liposomes containing sumatriptan in the treatment of migraine
por: Assadpour, Sara, et al.
Publicado: (2022)

Changes in the gene expression profile during spontaneous migraine attacks
por: Kogelman, Lisette J. A., et al.
Publicado: (2021)

The chronobiology of migraine: a systematic review
por: Poulsen, Amanda Holmen, et al.
Publicado: (2021)

Subcutaneous sumatriptan: results of a peculiar, unpublished, comparative, double-blind, randomised, and controlled trial
por: Tfelt-Hansen, Peer
Publicado: (2011)

A Randomized, Double-Blind, Placebo-Controlled Study of Breath Powered Nasal Delivery of Sumatriptan Powder (AVP-825) in the Treatment of Acute Migraine (The TARGET Study)
por: Cady, Roger K, et al.
Publicado: (2015)

Brain barriers and their potential role in migraine pathophysiology
por: Wiggers, Astrid, et al.
Publicado: (2022)

A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention
por: Ashina, Messoud, et al.
Publicado: (2020)

Sumatriptan–naproxen fixed combination for acute treatment of migraine: a critical appraisal
por: Khoury, Chaouki K, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_afr5e7hipaav6ds0clq1c0ud09